Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) malignancy - Pipeline Insight, 2021

This “Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Understanding

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy: Overview

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is regarded as an orphan tumour due to its rareness and usual clinical aggressiveness with poor response to conventional chemotherapies. It derives from precursors of plasmacytoid dendritic cells (pDCs), also known as professional type I interferon-producing cells or plasmacytoid monocytes. In the Revised WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, BPDCN is quoted after acute myeloid leukaemia. This reflects the fact that the gene signature of the cell of origin is much closer to myeloid than lymphoid precursors. It has a dismal prognosis, with most patients dying within one year when treated by conventional chemotherapies. The diagnosis is challenging, since neoplastic cells can resemble lymphoblasts or small immunoblasts, and require the use of a large panel of antibodies, including those against CD4, CD56, CD123, CD303, TCL1, and TCF4. The morphologic and in part phenotypic ambiguity explains the uncertainties as to the histogenesis of the neoplasm that led to the use of various denominations.

"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy pipeline landscape is provided which includes the disease overview and Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy treatment guidelines. The assessment part of the report embraces, in depth Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy R&D. The therapies under development are focused on novel approaches to treat/improve Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Emerging Drugs Chapters

This segment of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Emerging Drugs

• IMGN 632: ImmunoGen

IMGN632 is a CD123-targeting ADC in clinical development for hematological malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and acute lymphocytic leukemia (ALL). IMGN632 uses one of ImmunoGen's (the “Company”) novel indolinobenzodiazepine (IGN) payloads, which alkylate DNA without crosslinking. IGNs have been designed to have high potency against tumor cells, while demonstrating less toxicity to normal marrow progenitors than other DNA-targeting payloads.

The European Medicines Agency (EMA) granted orphan drug designation to IMGN632 for the treatment of BPDCN in June 2020; IMGN632 also holds this designation in the US. In October 2020, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for IMGN632 for the treatment of patients with relapsed or refractory BPDCN.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy: Therapeutic Assessment

This segment of the report provides insights about the different Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy

There are approx. 5+ key companies which are developing the therapies for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy. The companies which have their Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drug candidates in the most advanced stage, i.e. phase I/II include, ImmunoGen

The report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drugs.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Report Insights

• Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drugs?
• How many Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AbbVie
• ImmunoGen

Key Products

• Venetoclax
• IMGN 632
• Research programme: Allogeneic gene-edited chimeric antigen receptors T-cell therapy